RT Journal Article
SR Electronic
T1 Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides.
JF Molecular Pharmacology
JO Mol Pharmacol
FD American Society for Pharmacology and Experimental Therapeutics
SP 229
OP 233
VO 49
IS 2
A1 M D Hollenberg
A1 M Saifeddine
A1 B al-Ani
YR 1996
UL http://molpharm.aspetjournals.org/content/49/2/229.abstract
AB We measured in rat aorta rings the relaxant activity of a number of peptides derived from the activating sequence (SLIGRL, or PP6) of the proteinase-activated receptor-2 (PAR-2). The relaxant action of PP6-NH2 mimicked the action of low concentrations of trypsin (0.5-1 unit/ml; 1-2 nM), was dependent on an intact endothelium, and was blocked by N-omega-nitro-L-arginine methyl ester but not by N-omega-nitro-D-arginine methyl ester. The relaxant actions of PP6, SLIGRL-NH2 (PP6-NH2), SLIGR (PP5), and SLIGR-NH2 (PP5-NH2) were comparable in magnitude, with relative potencies of PP6-NH2 > or = PP6 > PP5-NH2 > PP5. Peptides lacking either a leucine at position 2 (SAIGRL) or an arginine at position 5 (SLIGAL) exhibited markedly reduced or no relaxant activity; nevertheless, the tetrapeptide LIGR-NH2 exhibited low but detectable intrinsic activity. With the use of reverse-transcriptase/polymerase chain reaction, we documented the presence of PAR-2 mRNA in aorta tissue and determined that the rat aorta amino-terminal receptor-activating sequence was the same as that reported for the murine PAR-2 receptor. We concluded that the rat aorta tissue has a PAR-2 receptor that can be activated by peptides as short as four amino acids; the leucine and arginine at positions 2 and 5, respectively, of the proteolytically revealed PAR-2 receptor-activating sequence play key roles in regulating receptor function.